GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors

Centre Hospitalier Universitaire, Amiens

Status: Completed

Conditions: Lung Tumor

Treatments: Other: Immunohistochemistry

Study type: Observational

Funder types: Other

Identifiers

NCT03645915

PI2017_843_0043

Details and patient eligibility

About

Lung neuroendocrine tumor (LNT) represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker.

GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT.

The team have assessed the GLUT1 immunohistochemical staining in 36 LNT and to assess its diagnostic value.

Full description

The (LNT) Lung neuroendocrine tumor represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker.

GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT.

Enrollment: 36 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with neuroendocrine tumors

Exclusion criteria

• Patients without neuroendocrine tumors